Thalidomide inhibits the replication of human immunodeficiency virus type 1.
S Makonkawkeyoon, R N Limson-Pobre, A L Moreira, V Schauf, G Kaplan
Index: Proc. Natl. Acad. Sci. U. S. A. 90 , 5974-5878, (1993)
Full Text: HTML
Abstract
Thalidomide, a selective inhibitor of tumor necrosis factor alpha (TNF-alpha) synthesis, suppresses the activation of latent human immunodeficiency virus type 1 (HIV-1) in a monocytoid (U1) line. The inhibition is dose dependent and occurs after exposure of the cells to recombinant TNF-alpha, phorbol myristate acetate, lipopolysaccharide, and other cytokine combinations. Associated with HIV-1 inhibition is a reduction in agonist-induced TNF-alpha protein and mRNA production. Thalidomide inhibition of virus replication in the phorbol myristate acetate- and recombinant TNF-alpha-stimulated T-cell line ACH-2 is not observed. The presence of thalidomide also inhibits the activation of virus in the peripheral blood mononuclear cells of 16 out of 17 patients with advanced HIV-1 infection and AIDS. These results suggest the use of thalidomide in a clinical setting to inhibit both virus replication and the TNF-alpha-induced systemic toxicity of HIV-1 and opportunistic infections.
Related Compounds
Related Articles:
2010-01-01
[Chem. Res. Toxicol. 23 , 171-83, (2010)]
2011-12-01
[J. Sci. Ind. Res. 65(10) , 808, (2006)]
Chemical genetics reveals a complex functional ground state of neural stem cells.
2007-05-01
[Nat. Chem. Biol. 3(5) , 268-273, (2007)]
2015-03-24
[Proc. Natl. Acad. Sci. U. S. A. 112(12) , E1471-9, (2015)]
2013-11-01
[Environ. Toxicol. 28(11) , 617-29, (2013)]